OncoMatch/Clinical Trials/NCT05603884
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Is NCT05603884 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen for leukemia, myeloid, acute.
Treatment: Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen — The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: BCR ABL1 translocation
chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hypomethylating agent
Participants have received the following treatments: hypomethylating agents
Cannot have received: (venetoclax)
Participants have received the following treatments: veneclax
Cannot have received: chemotherapy
Participants have received the following treatments: chemotherapy for myelodysplastic syndrome (MDS)
Cannot have received: solid organ transplantation
Participants have received the following treatments: solid organ transplantation
Lab requirements
Kidney function
estimated creatinine clearance ≥ 30 ml/min
Liver function
ast and alt ≤ 3.0 x uln (unless leukemic organ involvement). bilirubin ≤ 1.5 x uln (unless considered due to leukemic organ involvement)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify